Medical Device News Magazine

Medical Devices Pipeline Assessment on Clinical Chemistry Rapid Tests and POC

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

December 9, 2020

Medical devices pipeline assessment on clinical chemistry rapid tests and POC report is now available through Research and Markets. This report provides comprehensive information about the Clinical Chemistry Rapid Tests & POC pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Clinical chemistry rapid tests provide the test results immediately. These tests are used in low resource settings with the help of test strips, tablets and solutions.

Scope

  • Extensive coverage of the Clinical Chemistry Rapid Tests & POC under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Clinical Chemistry Rapid Tests & POC and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to Buy

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Clinical Chemistry Rapid Tests & POC under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date

Key Topics Covered:

1 Table of Contents

2 Introduction

3 Products under Development

3.1 Clinical Chemistry Rapid Tests & POC – Pipeline Products by Stage of Development

3.2 Clinical Chemistry Rapid Tests & POC – Pipeline Products by Territory

3.3 Clinical Chemistry Rapid Tests & POC – Pipeline Products by Regulatory Path

3.4 Clinical Chemistry Rapid Tests & POC – Pipeline Products by Estimated Approval Date

3.5 Clinical Chemistry Rapid Tests & POC – Ongoing Clinical Trials

4 Clinical Chemistry Rapid Tests & POC – Pipeline Products under Development by Companies

4.1 Clinical Chemistry Rapid Tests & POC Companies – Pipeline Products by Stage of Development

4.2 Clinical Chemistry Rapid Tests & POC – Pipeline Products by Stage of Development

5 Clinical Chemistry Rapid Tests & POC Companies and Product Overview

6 Clinical Chemistry Rapid Tests & POC- Recent Developments

7 Appendix

7.1 Methodology

7.2 About the Publisher

7.3 Contact

Companies Mentioned

  • Abreos Biosciences Inc
  • Acetaminophen Toxicity Diagnostics, LLC
  • Affinergy LLC
  • Am Biotechnologies, LLC
  • AnaZyme LLC
  • Angle Biosciences Inc
  • Atonomics A/S
  • Augurix SA
  • Baebies Inc
  • Base Pair Biotechnologies Inc
  • Biocross SL
  • Bioftalmik Applied Research
  • Biotech Resources Aust Pty Ltd
  • Boditech Med Inc
  • Burnet Institute
  • Carclo Diagnostic Solutions Ltd
  • CardioGenics Inc
  • Cellex Inc
  • Center for Biomedical Research Network in Bioengineering, Biomaterials and Nanomedicine
  • Claremont BioSolutions
  • Columbia University
  • CTK Biotech Inc
  • DiaSys Diagnostic Systems GmbH
  • Edan Instruments Inc
  • Enesi Pharma Ltd
  • Enigma Diagnostics Ltd (Inactive)
  • Erytech Pharma SA
  • FK-Biotecnologia SA
  • Foundation for Innovative New Diagnostics
  • Gendiag
  • Group K Diagnostics
  • Instrumentation Laboratory Co
  • Integrated Diagnostics Inc (Inactive)
  • IntraMed Diagnostics, LLC
  • IPI Singapore
  • Iron Horse Diagnostics, Inc.
  • Kenyatta University
  • Massachusetts Institute of Technology
  • Medical University of South Carolina
  • Monash University
  • Montana State University
  • NanoSpeed Diagnostics Inc
  • Novartis AG
  • Ohmx Corp
  • OPKO Health Inc
  • Oxford Immunotec Ltd
  • P2D Inc
  • Pennsylvania State University
  • Philips Healthcare
  • Pop Test LLC
  • PortaScience Inc
  • ProciseDx LLC
  • Quidel Corp
  • SaltCheck Inc (Inactive)
  • Seattle Children’s Hospital
  • SenGenix Inc
  • SuperNova Diagnostics, Inc.
  • Systagenix Wound Management Ltd
  • The University of New South Wales press Limited
  • Thermo Fisher Scientific Inc
  • Trivitron Healthcare Pvt Ltd
  • True Diagnostics Inc
  • Universal Biosensors Inc
  • University of Edinburgh
  • University of South Australia
  • UrSure Inc

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”